PT - JOURNAL ARTICLE AU - Park, Sang Woo AU - Noble, Brooklyn AU - Howerton, Emily AU - Nielsen, Bjarke F AU - Jiudice, Sarah S AU - Ambroggio, Lilliam AU - Dominguez, Samuel AU - Messacar, Kevin AU - Grenfell, Bryan T TI - Predicting the impact of non-pharmaceutical interventions against COVID-19 on <em>Mycoplasma pneumoniae</em> in the United States AID - 10.1101/2024.08.19.24312254 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.19.24312254 4099 - http://medrxiv.org/content/early/2024/08/20/2024.08.19.24312254.short 4100 - http://medrxiv.org/content/early/2024/08/20/2024.08.19.24312254.full AB - The introduction of non-pharmaceutical interventions (NPIs) against COVID-19 disrupted circulation of many respiratory pathogens and eventually caused large, delayed outbreaks, owing to the build up of the susceptible pool during the intervention period. In contrast to other common respiratory pathogens that re-emerged soon after the NPIs were lifted, longer delays (&gt; 3 years) in the outbreaks of Mycoplasma pneumoniae (Mp), a bacterium commonly responsible for respiratory infections and pneumonia, have been reported in Europe and Asia. As Mp cases are continuing to increase in the US, predicting the size of an imminent outbreak is timely for public health agencies and decision makers. Here, we use simple mathematical models to provide robust predictions about a large upcoming Mp outbreak in the US. Our model further illustrates that NPIs and waning immunity are important factors in driving long delays in epidemic resurgence.Competing Interest StatementB.N. and S.J. are employees of bioMerieux. bioMerieux markets the BIOFIRE System and Syndromic Trends. BIOFIRE and FilmArray are registered trademarks of BIOFIRE Diagnostics LLC in the United States and/or other countries. L.A's institution has received grant funding from Pfizer Inc. for an unrelated study. S.D. receives grant support from BIOFIRE Diagnostics, DelveBio, and Karius; he is also a consultant for BIOFIRE Diagnostics, DelveBio, and Karius.Funding StatementS.W.P. is a Peter and Carmen Lucia Buck Foundation Awardee of the Life Sciences Research Foundation. B.F.N. receives funding from Carlsberg Foundation (grant no. CF23-0173). K.M. receives funding as Principal Investigator of the NIAID Vaccine Research Center PREMISE EV-D68 Pilot Study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll code is stored in a publicly available GitHub repository (https://github.com/parksw3/mycoplasma_pred).